- $3.29m
- -$21.16m
- 19
- 55
- 62
- 42
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.11 | ||
| Price to Tang. Book | 0.11 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -112.43% | ||
| Return on Equity | -124.56% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Oncorus, Inc. is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The Company’s two product candidates from its self-amplifying RNA platform are ONCR-021 and ONCR-788. ONCR-021, a lead product candidate that is an IV administered viral RNA encoding an optimized genome of Coxsackievirus 21A (CVA21), is encapsulated within a lipid nanoparticle (LNP). The Company intends to develop ONCR-021 for non-small cell lung cancer, renal cell carcinoma, melanoma, anaplastic thyroid cancer, and hepatocellular carcinoma. The Company is also developing ONCR-788, which encodes for a modified version of the Seneca Valley Virus (SVV). The Company designed its HSV platform, including product candidate ONCR-719, to overcome the limitations in potency and in the ability to stimulate anti-tumor immunity that have both been encountered by previous viral immunotherapies and other immuno-oncology therapies.
Directors
- Mitchell Finer CHM (62)
- Theodore Ashburn PRE (54)
- John McCabe CFO (51)
- Steve Harbin COO (62)
- Christophe Queva SVP (53)
- John Goldberg SVP (48)
- Barbara Yanni DRC (67)
- Scott Canute IND (60)
- Luke Evnin IND (57)
- Mary Fenton IND (57)
- Spencer Nam IND (51)
- Eric Rubin IND (62)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- April 1st, 2015
- Public Since
- October 2nd, 2020
- No. of Shareholders
- 43
- No. of Employees
- 64
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 26,094,847
- Address
- 4 Corporate Drive, ANDOVER, 01810
- Web
- https://mpmcapital.com/
- Phone
- +1 8573206400
- Auditors
- Ernst & Young LLP
Upcoming Events for ONCR
Oncorus Inc Annual Shareholders Meeting
Q4 2023 Oncorus Inc Earnings Release
Q1 2024 Oncorus Inc Earnings Release
Similar to ONCR
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
Aeolus Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
What is the Oncorus share price?
As of Today at 18:16 UTC, shares in Oncorus are trading at $0.13. This share price information is delayed by 15 minutes.
How has the Oncorus share price performed this year?
Shares in Oncorus last closed at $0.13 and the price had moved by -50.63% over the past 365 days. In terms of relative price strength the Oncorus share price has underperformed the S&P500 Index by -58.69% over the past year.
What are the analyst and broker recommendations for Oncorus?
The overall consensus recommendation for Oncorus is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Oncorus dividend yield?
Oncorus does not currently pay a dividend.
Does Oncorus pay a dividend?
Oncorus does not currently pay a dividend.
When does Oncorus next pay dividends?
Oncorus does not currently pay a dividend.
How do I buy Oncorus shares?
To buy shares in Oncorus you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Oncorus?
As of the previous close price of $0.13, shares in Oncorus had a market capitalisation of $3.29m.
Where are Oncorus shares listed?
Here are the trading details for Oncorus:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ONCR
What kind of share is Oncorus?
Based on an overall assessment of its quality, value and momentum Oncorus is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Oncorus share price forecast for 2024?
The analyst consensus target price for shares in Oncorus is $5.00. That is 3868.25% above the last closing price of $0.13.
Analysts covering Oncorus currently have a consensus Earnings Per Share (EPS) forecast of -$1.60 for the next financial year.
Find out moreWhat is the trend in the Oncorus share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oncorus. Over the past six months, its share price has outperformed the S&P500 Index by +193.09%.
As of the last closing price of $0.13, shares in Oncorus were trading +1.7% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Oncorus PE Ratio?
The Oncorus PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.13.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Oncorus?
Oncorus' management team is headed by:
- Mitchell Finer - CHM
- Theodore Ashburn - PRE
- John McCabe - CFO
- Steve Harbin - COO
- Christophe Queva - SVP
- John Goldberg - SVP
- Barbara Yanni - DRC
- Scott Canute - IND
- Luke Evnin - IND
- Mary Fenton - IND
- Spencer Nam - IND
- Eric Rubin - IND